Company intelligence / Profile preview

BrePco Biopharma

Ownership: Private
Employees: ~1
Development stage: Commercial

Overview

The company has completed Phase III trials for a pediatric formulation of an inotrope (dopamine) used to treat hypotension in critically ill babies and children. Their product Neoatricon® (dopamine hydrochloride) is approved in the EU for pediatric patients.[1][2]

Therapeutic areas: Cardiovascular
Modalities: Small molecules (dopamine hydrochloride)
Industry: Biotech

Drug pipeline

1 asset

dopamine hydrochloride

Commercial

Indications: Hypotension in neonates, infants and children

Beyond the preview

Go deeper on BrePco Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BrePco Biopharma.

Explore the full profile